Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib With or Without Erlotinib in Papillary Renal Cell Carcinoma
NCT01688973Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivantinib in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Aug 2012; status: completed.
02
Drugs
tivantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01688973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688973.